| 证券代码 | NDRAU.O |
| 证券名称 | ENDRA Life Sciences Inc Unit Cons of 1 Sh + 1 Wt |
| 证券类型 | 美国普通单位 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2017-05-09 |
| 首发价格(元) | 5 USD |
| 首发数量(股) | 1680000 |
| 首发募资额(元) | 8,400,000.00 USD |
| 首发主承销商 | Dawson James Securities, Inc,Dougherty & Company LLC |
| 货币单位 | USD |
| 公司名称 | ENDRA Life Sciences Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 3600 Green Court, Suite 350, Ann Arbor, Michigan, USA |
| 成立日期 | 2007-07-18 |
| 董事会主席 | Francois Michelon |
| 公司属地 | United States 美国 |
| 公司网址 | endrainc.com |
| 电话 | +1 (734) 335-0468 |
| 传真 | - |
| 公司简介 | ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS) platform to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI - at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease (NAFLD). ENDRA's goal is to bring new capabilities to ultrasound - thereby broadening access to better healthcare. |